ARCHIVES

As FDA Weighs its Options on Morcellation, Debate Erupts Over Harvard Device Study

This article is from The Cancer Letter archive.

Vol. 40 No. 44 | November 21, 2014

Download PDF Visit The Full Archive

Related Articles

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

March 28, 2014

Harvest Yet To Come From Radiotherapy Advances, Kaplan Tells NCAB

October 17, 1975

NIH To Replace RAC With New Committee

July 19, 1996

Varmus Pledges No Funding Gap for NCORP, Blames Snafu On “Unclear Communication”

April 11, 2014

“Harm-Reduction” Products No Proven, IOM Report Says.

March 2, 2001

Hybridoma Cell Lines Available from NCI

September 3, 1982